PT  - JOURNAL ARTICLE
AU  - Wan Yang
AU  - Jeffrey Shaman
TI  - Epidemiological characteristics of three SARS-CoV-2 variants of concern and implications for future COVID-19 pandemic outcomes
AID  - 10.1101/2021.05.19.21257476
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.19.21257476
4099  - http://medrxiv.org/content/early/2021/05/21/2021.05.19.21257476.short
4100  - http://medrxiv.org/content/early/2021/05/21/2021.05.19.21257476.full
AB  - Three SARS-CoV-2 variants classified as variants of concern – B.1.1.7, B.1.351, and P.1 – have spread globally. To characterize their viral and epidemiological properties in support of public health planning, we develop and apply a model-inference system to estimate the changes in transmissibility and immune escape for each variant, based on case and mortality data from the country where each variant emerged. Accounting for under-detection of infection, disease seasonality, concurrent non-pharmaceutical interventions, and mass-vaccination, we estimate that B.1.1.7 has a 46.6% (95% CI: 32.3 – 54.6%) increase in transmissibility but nominal immune escape from protection induced by prior wild-type infection; B.1.351 has a 32.4% (95% CI: 14.6 – 48.0%) increase in transmissibility and 61.3% (95% CI: 42.6 – 85.8%) immune escape; and P.1 has a 43.3% (95% CI: 30.3 – 65.3%) increase in transmissibility and 52.5% (95% CI: 0 – 75.8%) immune escape. Model simulations indicate that B.1.351 and P.1 could supplant B.1.1.7 dominance and lead to increased infections. Our findings highlight the importance of preventing the spread of B.1.351 and P.1, in addition to B.1.1.7, via continued preventive measures, prompt mass-vaccination of all populations, continued monitoring of vaccine efficacy, and possible updating of vaccine formulations to ensure high efficacy.Competing Interest StatementJS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI.Funding StatementThis study was supported by the National Institute of Allergy and Infectious Diseases (AI145883), the National Science Foundation Rapid Response Research Program (RAPID; DMS2027369) and a gift from the Morris-Singer Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are publicly available as described in the Data sources and processing section.